Insights on the Jounce-Celgene collaboration and ICOS agonism

Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape

July 24, 2019

All that you leave behind

Integrated biomarker approaches are beginning to emerge to help researchers segment patients better for appropriate therapy. Here's one approach...

November 16, 2017

Why we should be cautiously optimistic about the cabiralizumab plus nivolumab data in pancreatic cancer

A look at the cabiralizumab plus nivolumab combination in PDAC at SITC over the weekend

November 15, 2017

Can entinostat overcome resistance to pembrolizumab?

A look st Syndax's entinostat and what happens when given in combination with pembrolizumab in melanoma and lung cancer

November 14, 2017

Nektar hits it out of the park at SITC 2017

A look at Nektar's promising IO portfolio and what's next for the up and coming biotech

November 13, 2017

The Stars from Day 2 of SITC17

Ten stars from the clinical presentations on Day 2 of SITC 2017

November 12, 2017

Interview with Dr Stephan Grupp on the JCAR015 ROCKET trial

A CAR T cell therapist's perspective on the Juno JCAR015 ROCKET dataset

November 11, 2017

SITC17 DAY 1 Highlights and Lowlights

A look at some of the main events from the first day at SITC 2017 - including Juno's ROCKET data.

November 10, 2017
National Harbor from Gaylord Hotel

SITC17 – Final Look at what to watch out for

Final SITC17 Preview and a look at key talks now that the abstracts are available.

November 8, 2017

Going beyond PD-L1 expression as a immune biomarker

What other approaches might be useful for predicting response (or non-response) to cancer immunotherapies?

October 19, 2017

SITC 2017 What to Watch for in Late Breaking Posters

A look at some of the LBA posters to be presented at #SITC17 in November

October 16, 2017
National Harbor Maryland

Five key late breakers to watch out for at SITC17

A look at 5 key oral late breakers at #SITC17 and what to expect or watch out for

October 13, 2017